Business
Cytokinetics Releases Inaugural Corporate Responsibility Report
Report Highlights Company Commitment to Patient Centricity, Sustainability, Ethics, Diversity, Equity and Inclusion SOUTH SAN FRANCISCO, Calif., March 27,
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"Report Highlights Company Commitment to Patient Centricity, Sustainability, Ethics, Diversity, Equity and Inclusion\nSOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the release of its inaugural Corporate Responsibility Report, outlining the Company's commitment to social and environmental responsibility, ethics and governance and patient and community engagement. “At Cytokinetics, being a responsible corporate citizen is a natural extension of our company values, and in order for us to be successful, our goals must be aligned to the well-being of our employees and the communities that we serve and in which we operate,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “Corporate responsibility has always been a fundamental core principle that we apply to our work in advancing potential therapies for those living with diseases of impaired muscle function; our inaugural report highlights our commitments and activities and formalizes our pledge to help ensure our plans and progress continue in accordance with our guiding values.” Cytokinetics’ inaugural report focuses on Empowering Lives in the communities it serves and highlights three strategic pillars as a framework for reporting. These pillars are: Keeping patients at the center of our workAdvancing a high-integrity, diverse and inclusive cultureSupporting sustainable communities The release of Cytokinetics’ inaugural Corporate Responsibility Report is part of its ongoing commitment to providing transparency and accountability on matters related to corporate responsibility. The Company intends to release an annual update to report on progress toward its goals and to ensure that all stakeholders are kept informed. For more information, please visit: www.cytokinetics.com/responsibility. About Cytokinetics Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is d...